D. Boral Capital reaffirmed their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) in a report published on Tuesday,Benzinga reports. The firm currently has a $32.00 price ...

Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary ...

As of December 31, 2024, cash and marketable securities were $127 million as compared to $152 million as of December 31, 2023, providing the ...

Shares of Compass Therapeutics (NASDAQ:CMPX) were up 8% in afternoon trading Monday after Guggenheim initiated coverage of ...

Compass Therapeutics' lead candidate, tovecimig, shows mixed data in various trials, with a significant upcoming phase 3 ...

Compass Therapeutics currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the sector are Castle Biosciences CSTL, BioMarin Pharmaceutical BMRN and Alnylam Pharmaceuticals ALNY.

Research analysts at Guggenheim began coverage on shares of Compass Therapeutics (NASDAQ:CMPX – Get Free Report) in a research note issued on Monday, MarketBeat reports. The firm set a “buy” rating ...

Highlights,Compass Therapeutics sees increased institutional engagement, with major firms expanding their holdings.,Research firms adjust ratings, reflecting varied perspectives on the company’s ...

Overview: Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company in the U.S. focused on developing antibody-based therapeutics for oncology, with a market cap of $429.28 million.

Shares of Compass Therapeutics CMPX have skyrocketed 108.3% in a month after the company announced updates regarding its pipeline development programs and current cash position. The phenomenal ...